The 22q11.2 Deletion Syndrome (22q11.2DS) is the most common microdeletion in humans with over 180 phenotypic expressions. Approximately 30–40% of affected individuals will develop psychosis and 25% meet the criteria for schizophrenia. Despite this, pharmacotherapy for managing psychosis in 22q11.2DS is poorly understood and 22q11.2DS psychosis is frequently labelled as treatment resistant. The objectives of this paper are to evaluate the effectiveness and tolerability of pharmacotherapy for 22q11.2DS psychosis and evaluate the evidence for treatment resistance.
Method:
A systematic search was performed using CINAHL, The Cochrane Library (Cochrane Database of Systematic Reviews; Cochrane Central Register of Controlled Trials and Cochrane Clinical Answers), EMBASE, PsycINFO, PubMed, Scopus and Web of Science Core Collection from inception to December 2022. It yielded 39 case reports, 6 case series and 1 retrospective study which met the inclusion criteria.
Results:
Based on the current literature, individuals with 22q11.2DS psychosis experience a greater rate of medical co-morbidities such as cardiac arrhythmias, seizures and movement disorders, which complicate pharmacotherapy. Poor tolerability rather than poor clinical response motivates the switching of antipsychotics, which may explain the labelling of treatment resistance in the literature.
Conclusion:
There are insufficient data to recommend a single antipsychotic for 22q11.2DS psychosis. Nonetheless, with proactive management of co-morbidities, antipsychotic medication in 22q11.2DS psychosis is an effective treatment commonly resulting in improvement in quality of life.
AccinniTFrascarelliMGhezziF, et al. (2021) Clozapine-induced gastroesophageal rumination in 22q11.2 deletion syndrome. A case report on gastroesophageal side effects management without renouncing clozapine’s effectiveness. Clinical Case Reports9: e04134.
2.
AksuHDemirkayaSK (2016) Treatment of schizophrenia by clozapine in an adolescent girl with DiGeorge syndrome. Journal of Child and Adolescent Psychopharmacology26: 652.
3.
AlkanTAkçevinATürkogluH, et al. (2006) Shprintzen (velo-cardio-facial) syndrome: A rare case. ASAIO Journal52: e33–e34.
4.
AngelopoulosETheleritisCEconomouM, et al. (2017) Antipsychotic treatment of 22q112 deletion syndrome-related psychoses. Pharmacopsychiatry50: 162–163.
5.
AngkustsiriKGoodlin-JonesBDepreyL, et al. (2014) Social impairments in chromosome 22q11.2 deletion syndrome (22q11.2DS): Autism spectrum disorder or a different endophenotype?Journal of Autism and Developmental Disorders44: 739–746.
BiswasABHandsOWhiteJ (2008) Velocardiofacial syndrome in intellectual disability: Borderline personality disorder behavioral phenotype and treatment with clozapine – A case report. Mental Health Aspects of Developmental Disabilities11: 94–100.
8.
BlagojevicCHeungTTheriaultM, et al. (2021) Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: A cross-sectional analysis from population-based newborn screening. CMAJ Open9: E802–E809.
BootEButcherNJvan AmelsvoortTA, et al. (2015a) Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. American Journal of Medical Genetics Part A 167A: 639–645.
11.
BootEButcherNJVorstmanJA, et al. (2015b) Pharmacological treatment of 22q112 deletion syndrome-related psychoses. Pharmacopsychiatry48: 219–220.
12.
BordersCBSuzukiASafaniD (2017) Treatment of 22q11.2 deletion syndrome-associated schizophrenia with comorbid anxiety and panic disorder. Mental Illness9: 7225.
13.
BortolinKDelavariFPretiMG, et al. (2022) Neural substrates of psychosis revealed by altered dependencies between brain activity and white-matter architecture in individuals with 22q11 deletion syndrome. NeuroImage: Clinical35: 103075.
14.
BoultonAThompsonA (2018) The clue in the face: An unusual first episode psychosis presentation. Australian and New Zealand Journal of Psychiatry52: 293–294.
15.
ButcherNJBootELangAE, et al. (2018) Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. American Journal of Medical Genetics Part A176: 2146–2159.
16.
ButcherNJFungWLFitzpatrickL, et al. (2015) Response to clozapine in a clinically identifiable subtype of schizophrenia. The British Journal of Psychiatry206: 484–491.
17.
CarandangCGScholtenMC (2007) Metyrosine in psychosis associated with 22q11.2 deletion syndrome: Case report. Journal of Child and Adolescent Psychopharmacology17: 115–120.
18.
ChoiSHKangSGKimHY, et al. (2020) Important consideration in choosing antipsychotics in the treatment of patients with 22q11.2 deletion syndrome: Risk of convulsion. Clin Psychopharmacol Neurosci18: 454–457.
19.
ChowLYGarcia-BarceloMWingYK, et al. (1999) Schizophrenia and hypocalcaemia: Variable phenotype of deletion at chromosome 22q11. Australian and New Zealand Journal of Psychiatry33: 760–762.
20.
ChowLYWayeMMYGarcia-BarceloM, et al. (1998) Velo-cardio-facial syndrome, schizophrenia at chromosome 22q11. Journal of Intellectual Disability Research42: 184–188.
21.
Ciano-PetersenNLHamad-CuetoODrissi-ReyesH, et al. (2021) Case report: Autoimmune psychosis in chromosome 22q11.2 deletion syndrome. Frontiers in Immunology12: 708625.
22.
De BoerJBootEvanGilsL, et al. (2019) Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review. American Journal of Medical Genetics. Part A179: 2292–2306.
23.
DoriNGreenTWeizmanA, et al. (2017) The effectiveness and safety of antipsychotic and antidepressant medications in individuals with 22q11.2 deletion syndrome. Journal of Child and Adolescent Psychopharmacology27: 83–90.
24.
DuarteMAfonsoJMoreiraA, et al. (2017) Hyperprolinemia as a clue in the diagnosis of a patient with psychiatric manifestations. Brain & Development39: 539–541.
25.
EngebretsenMHKildahlANHoyIH, et al. (2019) Metyrosine treatment in a woman with chromosome 22q11.2 deletion syndrome and psychosis: A case study. International Journal of Developmental Disabilities65: 116–121.
26.
FaeddaGLGrafWShprintzenR (2016) Treatment of velo-cardio-facial syndrome-related psychosis with metyrosine. Journal of the American Academy of Child and Adolescent Psychiatry55: S169.
27.
FaeddaGLWachtelLEHigginsAM, et al. (2015) Catatonia in an adolescent with velo-cardio-facial syndrome. American Journal of Medical Genetics Part A 167A: 2150–2153.
28.
FiksinskiAMSchneiderMZinkstokJ, et al. (2021) Neurodevelopmental trajectories and psychiatric morbidity: Lessons learned from the 22q11.2 deletion syndrome. Current Psychiatry Reports23: 13.
29.
FranciscoAAFoxeJJHorsthuisDJ, et al. (2022) Early visual processing and adaptation as markers of disease, not vulnerability: EEG evidence from 22q11.2 deletion syndrome, a population at high risk for schizophrenia. Schizophrenia8: 28.
30.
FungWLButcherNJCostainG, et al. (2015) Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genetics in Medicine17: 599–609.
31.
GalletlyCCastleDDarkF, et al. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry50: 410–472.
32.
GargVPaiN (2011) Neuropsychiatric manifestation of velo cardio facial syndrome – A review. Australian and New Zealand Journal of Psychiatry45: A61.
33.
GladstonSClarkeDJ (2005) Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: Benefits and risks. Journal of Intellectual Disability Research49: 567–570.
34.
GothelfD (2015) Risk factors for schizophrenia and psychiatric treatments in 22q11.2 deletion syndrome. European Neuropsychopharmacology25: S118.
35.
HasogluTWaxmonskyJGBawejaR (2020) Recurrent mania in an adolescent with velocardiofacial syndrome and treatment challenges. Bipolar Disorders22: 876–878.
36.
HedgesDJeppsonKWhiteheadP (2003) Antipsychotic medication and seizures: A review. Drugs of Today (Barcelona, Spain: 1998)39: 551–557.
37.
HilkerRHeleniusDFagerlundB, et al. (2018) Heritability of schizophrenia and schizophrenia spectrum based on the Nationwide Danish Twin Register. Biological Psychiatry83: 492–498.
38.
KeepersGAFochtmannLJAnziaJM, et al. (2020) The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. The American Journal of Psychiatry177: 868–872.
39.
KimGMoonEParkJM, et al. (2020) Various psychiatric manifestation in DiGeorge syndrome (22q11.2 deletion syndrome): A case report. Clinical Psychopharmacology and Neuroscience18: 458–462.
40.
KontoangelosKLazaratouEEconomouM, et al. (2020) Efficacy of low-dose aripiprazole for treatment of psychotic symptoms in a patient with 22q11.2 deletion syndrome. Psychopharmacology Bulletin50: 35–39.
41.
KontoangelosKMaillisAMaltezouM, et al. (2015) Acute dystonia in a patient with 22q11.2 deletion syndrome. Mental Illness7: 30–31.
42.
KookSDAnSKKimKR, et al. (2010) Psychotic features as the first manifestation of 22q I I.2 deletion syndrome. Psychiatry Investigation7: 72–74.
43.
KrahnLEMaraganoreDMMichelsVV (1998) Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22. Mayo Clinic Proceedings73: 956–959.
44.
KrefftMFrydeckaDŚmigielR, et al. (2020) Metabolic parameters in patients with Prader-Willi syndrome and DiGeorge syndrome with respect to psychopathological manifestation. Neuropsychiatric Disease and Treatment16: 457–463.
45.
LaddhaSSchwartzAC (2014) Number variant analysis in a hospitalized patient with psychosis. Psychosomatics55: 500–505.
46.
LinCEHwangKSHsiehPH, et al. (2010) Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry34: 1141–1143.
47.
ManciniVMaederJBortolinK, et al. (2021) Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome. Translational Psychiatry11: 336.
48.
MattejatFRemschmidtH (2008) The children of mentally ill parents. Deutsches Ärzteblatt International105: 413–418.
49.
MolebatsiKOlashoreAA (2018) Early-onset psychosis in an adolescent with DiGeorge syndrome: A case report. The South African Journal of Psychiatry24: 1164.
50.
MooreTMSalzerDBeardenCE, et al. (2021) Inter-rater reliability of subthreshold psychotic symptoms in individuals with 22q11.2 deletion syndrome. Journal of Neurodevelopmental Disorders13: 23.
51.
MoshevaMKorotkinLGurRE, et al. (2020) Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: A systematic review. European Child & Adolescent Psychiatry29: 1035–1048.
52.
MüllerUJFellgiebelA (2008) Successful treatment of long-lasting psychosis in a case of 22q11.2 deletion syndrome. Pharmacopsychiatry41: 158–159.
53.
NehmeRPietiläinenOArtomovM, et al. (2022) The 22q11.2 region regulates presynaptic gene-products linked to schizophrenia. Nature Communications13: 3690.
54.
NiarchouMChawnerSJRAFiksinskiA, et al. (2019) Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome. Schizophrenia Research204: 320–325.
55.
NICE (2014) Psychosis and Schizophrenia in Adults: Prevention and Management Clinical Guideline. London: National Institute for Health and Care Excellence.
56.
NicoteraAGDi RosaGTurrizianiL, et al. (2021) Role of COMT V158M polymorphism in the development of dystonia after administration of antipsychotic drugs. Brain Sciences11: 1293.
57.
O’HanlonJFRitchieRCSmithEA, et al. (2003) Replacement of antipsychotic and antiepileptic medication by L-α-methyldopa in a woman with velocardiofacial syndrome. International Clinical Psychopharmacology18: 117–119.
58.
OhiKHashimotoRYamamoriH, et al. (2013) How to diagnose the 22q11.2 deletion syndrome in patients with schizophrenia: A case report. Annals of General Psychiatry12: 29.
59.
PerretLCLodovighiMAPerretO, et al. (2017) Treatment of comorbid bipolar disorder improves disabilities and neuropsychological functioning in DiGeorge syndrome: A case report. Journal of Clinical Psychopharmacology37: 736–738.
60.
PillingerTMcCutcheonRAVanoL, et al. (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry7: 64–77.
61.
RadoevaPDFremontWAntshelKM, et al. (2017) Longitudinal study of premorbid adjustment in 22q11.2 deletion (velocardiofacial) syndrome and association with psychosis. Development and Psychopathology29: 93–106.
62.
RuheAMQureshiIProcacciniD (2018) Clozapine-induced myocarditis in an adolescent male with DiGeorge syndrome. The Mental Health Clinician8: 313–316.
63.
SachdevP (2002) Schizophrenia-like illness in velo-cardio-facial syndrome: A genetic subsyndrome of schizophrenia?Journal of Psychosomatic Research53: 721–727.
64.
SchneiderMArmandoMSchultze-LutterF, et al. (2019) Prevalence, course and psychosis-predictive value of negative symptoms in 22q11.2 deletion syndrome. Schizophrenia Research206: 386–393.
65.
ShprintzenRJ (2008) Velo-cardio-facial syndrome: 30 Years of study. Developmental Disabilities Research Reviews14: 3–10.
66.
SiskindDOrrSSinhaS, et al. (2022) Rates of treatment-resistant schizophrenia from first-episode cohorts: Systematic review and meta-analysis. The British Journal of Psychiatry220: 115–120.
67.
SønderbyIEChingCRKThomopoulosSI, et al. (2022) Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. Human Brain Mapping43: 300–328.
68.
StarlingJHarrisAW (2008) Case reports: An opportunity for early intervention: Velo-cardio-facial syndrome and psychosis. Early Intervention in Psychiatry2: 262–267.
69.
TangKLAntshelKMFremontWP, et al. (2015) Behavioral and psychiatric phenotypes in 22q11.2 deletion syndrome. Journal of Developmental and Behavioral Pediatrics36: 639–650.
70.
TanifujiTOtsukaIKimuraA, et al. (2022) Successful electroconvulsive therapy for 22q11.2 deletion syndrome with Schizophrenia and Parkinson’s disease. Psychiatry and Clinical Neurosciences76: 603–604.
71.
TastuzawaYSekikawaKSudaT, et al. (2015) An interictal schizophrenia-like psychosis in an adult patient with 22q11.2 deletion syndrome. Epilepsy & Behavior Case Reports3: 36–38.
72.
ThomasZS (2003) Psychosis, electrolyte imbalance, and velocardiofacial syndrome. Psychosomatics44: 348–350.
73.
ToyosimaMMaekawaMToyotaT, et al. (2011) Schizophrenia with the 22q11.2 deletion and additional genetic defects: Case history. The British Journal of Psychiatry199: 245–246.
74.
Van der MeijsMESchweitzerDHBoomH (2021) Palatoschisis, Schizophrenia and Hypocalcaemia: Phenotypic expression of 22q11.2 deletion syndrome (DiGeorge syndrome) in an adult. European Journal of Case Reports in Internal Medicine8: 002411.
75.
VanLHeungTGraffiJ, et al. (2019) All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine21: 2328–2335.
VerhoevenWMEggerJI (2015b) Atypical antipsychotics and relapsing psychoses in 22q112 deletion syndrome: A long-term evaluation of 28 patients. Pharmacopsychiatry48: 104–110.
78.
VerhoevenWMAEggerJIMde LeeuwN (2018) Relevance of deletion breakpoint specification in 22q11.2 deletion syndrome: Clinical management of three illustrative patients. Clinical Neuropsychiatry15: 306–310.
79.
VingerhoetsCTseDCeccariniJ, et al. (2021) Dopamine, glutamate and the relation with cognition in 22q11.2 deletion syndrome: A [18F]fallypride Pet and 7-Tesla 1H-MRS study. Biological Psychiatry89: S162.
80.
VingerhoetsCTseDHYvan AmelsvoortT (2019) Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case. European Journal of Medical Genetics62: 103705.
81.
VollSLBootEButcherNJ, et al. (2017) Obesity in adults with 22q11.2 deletion syndrome. Genetics in Medicine19: 204–208.
82.
WoestelandtLNovoAPhilippeA, et al. (2018) PDD-NOS, psychotic features and executive function deficits in a boy with proximal 22q11.2 microduplication: Evolution of the psychiatric symptom profile from childhood to adolescence. European Journal of Medical Genetics61: 280–283.
83.
YacoubAAybarM (2007) Response to clozapine in psychosis associated with velo-cardio-facial syndrome. Psychiatry (Edgmont)4: 14.
84.
YanWJacobsenLKKrasnewichDM, et al. (1998) Chromosome 22q11.2 interstitial deletions among childhood-onset schizophrenics and ‘multidimensionally impaired’. American Journal of Medical Genetics81: 41–43.
85.
ZöllerDSandiniCSchaerM, et al. (2021) Structural control energy of resting-state functional brain states reveals less cost-effective brain dynamics in psychosis vulnerability. Human Brain Mapping42: 2181–2200.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
